narrative_review·infectious disease, preclinical research, immunology, research methods, pulmonology·PMC10634178
Advanced drug delivery and therapeutic strategies for tuberculosis treatment
Journal of Nanobiotechnology · 9 authors, 6 centres
AI SUMMARY
FIDELITY 100%
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This narrative review summarizes advanced drug delivery systems, such as nanoparticles and liposomes, and therapeutic strategies, like vaccines, for improving tuberculosis treatment. It concludes that these approaches have the potential to enhance drug efficacy, patient adherence, and overcome challenges like drug resistance, but clinical translation remains slow.
Full summary
898 CHARS
It describes various preclinical and translational technologies, including nanoparticles, liposomes, microparticles, and vaccine formulations (e.g., ID93/GLA-SE, RUTI®), designed to improve drug bioavailability, targeting, and sustained release to enhance efficacy and patient adherence. The review highlights that these technologies can address key challenges such as poor solubility, inability to penetrate alveolar macrophages, and side effects. It notes promising preclinical data and references several ongoing clinical trials (e.g., NCT03722472, NCT04919239) for vaccine candidates. A central conclusion is that while advanced delivery strategies show potential to revolutionize TB therapy, significant research gaps remain, including optimizing delivery systems for targeted delivery, enhancing biocompatibility, and navigating regulatory approval to achieve successful clinical translation.
